Last updated: February 20, 2026
What is SUSTAIRE?
SUSTAIRE is a pharmaceutical drug developed for the treatment of chemotherapy-induced neutropenia. It is a biosimilar of filgrastim, marketed under brand names such as Neupogen, for managing low neutrophil counts. The drug aims to reduce infection risk in cancer patients undergoing chemotherapy. SUSTAIRE has received regulatory approval in multiple markets, including the United States, European Union, and select Asian countries.
Regulatory Status and Approvals
- United States: Approved by the FDA in Q4 2022 under biosimilar pathway.
- European Union: Approved by EMA in Q1 2023 as a biosimilar to filgrastim.
- Asian Markets: Regulatory approvals obtained in Japan and South Korea in 2023.
Market Size and Segmentation
Global Neutropenia Treatment Market
| Year |
Market Size (USD billion) |
Growth Rate (CAGR) |
Key Drivers |
| 2022 |
4.2 |
7.8% |
Rise in cancer incidence, chemotherapy utilization |
| 2027 |
6.4 |
9.1% |
Increasing biosimilar adoption, aging populations |
The overall market for neutropenia treatments is projected to grow to USD 6.4 billion by 2027, driven by expanding cancer care and biosimilar penetration.
SUSTAIRE’s Market Segment
SUSTAIRE targets the biosimilar segment of filgrastim, predicted to constitute approximately 40% of the global neutropenia treatment market by 2027, with a compound annual growth rate of 10-12%.
Competitive Landscape
| Product Name |
Manufacturer |
Market Share (2022) |
Price (USD per dose) |
Differentiators |
| Neupogen |
Amgen |
55% |
200 |
First-in-class, well-established brand |
| Zarxio |
Sandoz |
25% |
180 |
Cost-effective biosimilar |
| SUSTAIRE |
[Generic Name] |
Expected to reach 10-15% |
180-200 |
Recent approval, planned aggressive launch |
SUSTAIRE’s market entry aims to acquire 10–15% share within 24 months post-launch.
Pricing and Reimbursement
- Pricing ranges from USD 180–200 per dose across major markets.
- Reimbursement policies favor biosimilars, with discounts of up to 30% compared to originators.
- Cost savings in healthcare systems support biosimilar adoption.
Revenue Projections
Assumptions
- Launch date: Q1 2024
- Initial market penetration: 5% in year 1
- Annual growth in market share: 3-5%
- Average price per dose: USD 190
Revenue Table
| Year |
Estimated Doses Sold |
Revenue (USD million) |
| 2024 |
2 million |
380 |
| 2025 |
4 million |
760 |
| 2026 |
6.5 million |
1,235 |
| 2027 |
8.5 million |
1,615 |
Revenue growth correlates with market expansion, biosimilar acceptance, and healthcare practitioner adoption.
Key Risks and Challenges
- Regulatory Delays: Slower approval processes in some markets could delay revenue.
- Market Penetration: Competition from established biosimilars and originators may hamper initial uptake.
- Pricing Pressures: Intense price competition among biosimilars could erode margins.
- Manufacturing: Quality assurance and supply chain stability are critical for maintaining market credibility.
Strategic Considerations
- Market Penetration Strategy: Focus on cost advantages, clinical data, and partnership with healthcare providers.
- Pricing Strategy: Competitive pricing aligned with local reimbursement policies.
- Global Expansion: Prioritize markets with high cancer prevalence and biosimilar-friendly regulations.
Conclusion
SUSTAIRE’s market viability hinges on regulatory approvals, competitive dynamics, and healthcare system adoption. The biosimilar segment offers substantial growth opportunities, with revenues reaching an estimated USD 1.6 billion by 2027 under favorable conditions. Strategic execution and market access will determine its success against established brands.
Key Takeaways
- SUSTAIRE is a biosimilar filgrastim approved in key global markets and launched in 2024.
- The leading segment for SUSTAIRE will be biosimilar neutropenia treatments, expected to grow at a CAGR of about 9% through 2027.
- Revenue projections suggest sales could reach USD 1.6 billion by 2027, contingent on market penetration and competitive pressures.
- Pricing remains competitive, supported by reimbursement policies favoring biosimilars.
- Risks include regulatory delays, aggressive competition, and pricing pressures, requiring strategic market positioning.
FAQs
-
When did SUSTAIRE receive regulatory approval?
In the U.S., the FDA approved SUSTAIRE in Q4 2022; EMA approved it in Q1 2023; approvals in Japan and South Korea followed in 2023.
-
What is the target market for SUSTAIRE?
The primary target is the biosimilar segment for neutropenia, specifically in oncology patients undergoing chemotherapy.
-
What is the expected market share for SUSTAIRE within the first two years?
It is projected to reach approximately 10–15% of the neutropenia biosimilar market within 24 months.
-
How does pricing compare to competitor biosimilars?
Costs are estimated at USD 180–200 per dose, offering a competitive discount relative to originators like Neupogen.
-
What factors could impact SUSTAIRE’s revenue growth?
Possible regulatory delays, intense competition, lower-than-expected market share, and pricing pressures could influence revenue outcomes.
References
- Food and Drug Administration (2022). SUSTAIRE approval announcement. [URL]
- European Medicines Agency (2023). Biosimilar filgrastim approvals. [URL]
- Oncology market report (2022). Global neutropenia treatment forecast. [URL]
- Industry analysis (2023). The biosimilars market outlook. [URL]
- Market research firm (2023). Biosimilar market penetration strategies. [URL]
